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Summary
An increasing proportion of the worldwide population is affected by allergic diseases such
as allergic rhinitis (AR), atopic dermatitis (AD) and allergic asthma and improved treatment
options are needed particularly for severe, refractory disease. Allergic diseases are complex
and development involves both environmental and genetic factors. Although the existence
of a genetic component for allergy was first described almost 100 years ago, progress in
gene identification has been hindered by lack of high throughput technologies to investi-
gate genetic variation in large numbers of subjects. The development of Genome-Wide
Association Studies (GWAS), a hypothesis-free method of interrogating large numbers of
common variants spanning the entire genome in disease and non-disease subjects has
revolutionised our understanding of the genetics of allergic disease. Susceptibility genes
for asthma, AR and AD have now been identified with confidence, suggesting there are
common and distinct genetic loci associated with these diseases, providing novel insights
into potential disease pathways and mechanisms. Genes involved in both adaptive and
innate immune mechanisms have been identified, notably including multiple genes
involved in epithelial function/secretion, suggesting that the airway epithelium may be
particularly important in asthma. Interestingly, concordance/discordance between the
genetic factors driving allergic traits such as IgE levels and disease states such as asthma
have further supported the accumulating evidence for heterogeneity in these diseases.
While GWAS have been useful and continue to identify novel genes for allergic diseases
through increased sample sizes and phenotype refinement, future approaches will integrate
analyses of rare variants, epigenetic mechanisms and eQTL approaches, leading to greater
insight into the genetic basis of these diseases. Gene identification will improve our under-
standing of disease mechanisms and generate potential therapeutic opportunities.
Atopic disease and evidence of a familial component
Allergy is a hypersensitive inflammatory immune
response to innocuous environmental antigens, medi-
ated by immunoglobulin type E (IgE) antibodies. By
definition, this is the underlying cause of all allergic
disease, although there is significant heterogeneity
between different allergic conditions, such as allergic
asthma, atopic dermatitis (AD) (eczema) and seasonal
allergic rhinitis (AR) (hay fever). The prevalence of
allergic disease has increased globally in the last few
decades and more than a third of the UK population are
affected by some form of allergy, which is accompanied
by significant economic burden [1–5].
The development of allergic disease is complex and
not fully understood, with both environmental and
genetic components. Environmental changes are
thought to have contributed to the increased incidence
of allergy in recent years with evidence for a role for
tobacco smoke exposure, respiratory viral infections,
use of antibiotics, diet and exposure to allergens to
name a few. The first study to identify the heritability
of allergy found that 48.4% of a group of 621 sensitised
individuals had a family history of sensitisation to com-
mon environmental allergens, compared with only
14.5% of the control group of 76 non-sensitised
individuals [6]. A few years later, the term atopy was
first coined, to mean inherited hypersensitivity [7].
More recent studies in twins provide further evidence
for allergy heritability, due to the higher levels ofAll authors contributed equally.
concordance for allergic phenotypes in monozygotic,
compared with dizygotic twins, where atopy heritability
is estimated between 50% and 84% [8–10]. Heritability
estimates for allergic disease vary, but have been
described as high as 95% for asthma, 91% for AR and
84% for AD (reviewed [11]).
Different allergic diseases are related by overlapping
aetiology, i.e. elevated IgE, therefore co-morbidity due
to a genetic component is logical. However, other fac-
tors are important within the disease per se, e.g. non-
IgE mechanisms in asthma. Initial allergic sensitisation
occurs on exposure to an allergen breaching the epithe-
lial barrier, due to disruption or dysfunction, which
may have genetic and/or environmental causes (Fig. 1).
Specifically, disruption of the epidermal barrier is con-
sidered to be the first step in the development of
eczema. This cutaneous sensitisation might then become
systemic and subsequently give rise to other allergies,
such as AR; this phenomenon is referred to as ‘atopic
march’ and contributes to co-morbidity of allergies
[12].
In this review, we will provide an overview to the
current status of the genetics of asthma, AD and AR
including related allergic traits; serum IgE, sensitisation
and blood eosinophil counts with a focus to Genome-
Wide Association Studies.
Methods for identifying genes associated with complex
diseases
Our understanding of the extent and nature of variation
in the human genome has significantly improved fol-
lowing the first draft genome sequence in 2001. Recent
figures suggest that > 20 million single nucleotide
polymorphisms (SNP) or single base pair changes, exist
out of a 3-billion-base pair genome. Early methods
used to map genes of relevance in allergic disease
included linkage analysis (mainly 1980–19900s) and
candidate gene association studies (1970’s – present).
Reproducibility of linkage and association approaches
was disappointing primarily due to inadequate power,
subject heterogeneity (different phenotype definition),
population stratification and multiple testing without
correction. This has generally led to inconsistent results;
however, several genes have been identified with confi-
dence, e.g. DPP10, PCDH1, HLAG, NPSR1, PHF11,
PLAUR, ADAM33, IL10, CD14, IL4, IL13, ADRB2,
HLA-DRB1, HLA-DQB1, TNFA, FCER1B, INPP4A,
STAT6 and IL4RA for asthma, e.g. COL6A5, FLG, TLR9,
IL13, SPINK5, CMA1, IL4RA and RANTES for AD and
FLG, S100A7, HDC, IL13, IL6, TLR7 for AR (reviewed
[11, 13, 14]). Of special note is the identification of fil-
aggrin (FLG) as a susceptibility gene for AD. Several
polymorphisms and loss of function mutations within
FLG, a gene that can influence the epidermal barrier,
cause increased susceptibility to AD [15]. Carriers of
specific SNPs of FLG can have an approximately three-
fold greater chance of developing AD compared to
non-carriers. This effect size is particularly large for a
complex trait and exemplifies the usefulness of genetics
to identify altered biology in disease (reviewed [16]).
Genome-Wide Association Studies in allergic disease
GWAS is the current method of choice for gene
identification in complex disorders, which involves
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Fig. 1. Development of allergy. Both environmental and genetic factors influence barrier integrity and sensitisation to common environmental
allergens. This can lead to a Th2-dominant environment, elevated IgE levels, and allergic phenotypes that affect a variety of organs.
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examining association with typically 500 000+ com-
mon (> 5% frequency) polymorphisms spanning the
entire genome in cases and controls with very stringent
statistical thresholds, e.g. P < 5 9 108. In the follow-
ing sections, we provide an overview of current find-
ings of recent GWAS for i) self-reported/doctor-
diagnosed asthma, AR and AD and ii) measures of
allergic disease including total serum IgE, allergic sensi-
tisation and blood eosinophil counts.
Genetic risk factors associated with self-reported/
doctor-diagnosed allergic disease
Asthma, AR and AD are clinically diagnosed as discrete
diseases; however, the interrelationship between these
diseases has long been recognised. For example, indi-
viduals with AR have a 5–6-fold greater risk of devel-
oping asthma [17, 18]. Similarly, it is established that
there are shared and distinct genetic components to
these diseases with correlation estimates at 0.55 for
asthma and eczema, at 0.47 for asthma and rhinitis and
at 0.62 for eczema and rhinitis [19]. In the following
sections, we will outline recent findings from GWAS of
these diseases; however, it is important to note that few
have taken into account co-morbidities in recruitment
strategies.
Asthma
The first GWAS for asthma was completed in 2007 by
Moffatt and colleagues, a discovery cohort of 994
patients with childhood onset asthma and 1243 non-
asthma controls identified significant association to a
locus on chromosome 17q21 [20]. This locus included
genes for zona pellucida binding protein 2 (ZPBP2), gas-
dermin B (GSDMB) and orm1-like protein 3 (ORMDL3).
The 17q21 locus has been reproduced as a locus associ-
ated with asthma [21], severe asthma [22] and asthma
with severe exacerbations [23] in subsequent GWAS.
Similarly, SNPs in the 17q21 locus are associated with
several clinical measures in multiple asthma cohorts,
including lung function, bronchial hyper-responsiveness
and disease severity [24, 25]. The identification of the
specific gene(s) underlying these effects remains to be
resolved; ZPBP2, GSDMB and ORMDL3 have been impli-
cated in gene transcription, cell apoptosis and sphingo-
lipid synthesis, respectively. Recently, a role for ORMDL3
in eosinophil trafficking and degranulation, mechanisms
thought to be important in asthma, has been identified
[26]. Similarly, a role for sphingolipid synthesis in deter-
mining bronchial reactivity [27] and a role for the endo-
plasmic reticulum unfolded protein-response pathway as
a mechanism by which ORMDL3 is linked to asthma,
have been reported [28]. It is important to note that the
effect of ORMDL3 polymorphisms has been shown to be
significantly influenced by the age of onset of asthma,
with the effect being particularly important in childhood
asthma [20]. This is a relevant point as several asthma
phenotype cluster analyses have identified that the age of
asthma onset was amongst the strongest factors in
discriminating different asthma phenotypes [29–31].
Subsequent GWAS in asthma have now identified
around 13 susceptibility loci with confidence in the
Caucasian population (Table 1). It is important to note
that in the GWAS in asthma and other allergic diseases
most single variants confer a very modest odds ratio of
1.1–1.3 to develop disease; however, this has also been
observed in other complex disorders. Of note is the
largest GWAS for asthma completed to date by the
GABRIEL consortium which involved 10 365 cases and
16 110 controls [21]. This study identified association
between polymorphisms spanning IL33, IL1RL1/
IL18R1, HLA-DQ, SMAD3, IL2RB, the 17q21 locus and
asthma [21]. These genes represent a novel insight into
potential molecular mechanisms underlying asthma,
e.g. HLA would be anticipated to be important for
T-cell-mediated responses, SMAD3 is a signalling inter-
mediate involved in fibrosis and IL2RB for T cell sur-
vival. However, the finding that both the interleukin 33
(IL33) and interleukin 33 receptor (IL1RL1 or ST2)
genes were identified is of relevance as GWAS examin-
ing allergic sensitisation and blood eosinophilia have
also identified these two loci (Table 2). Subsequent
GWAS have replicated the association signal to IL33
for severe asthma with exacerbation [23] and to IL1RL1
for asthma [32] and severe asthma [22]. Interestingly, in
this recent study of severe asthma with exacerbation,
the effect sizes for individual polymorphisms at multi-
ple loci including IL33 key SNPs were increased with
number of hospitalisations per genotype (e.g. OR 1.32,
1.22, 1.47, 1.91 for 2, 3, 4/5 and 6 or more hospitalisa-
tions, respectively) [23]. There is accumulating evidence
that the IL33/IL1RL1 axis may be of relevance in
asthma. IL33 has been shown to be elevated in the air-
ways of asthma patients, particularly in the airway
structural cells including the bronchial epithelium [33].
In addition, a soluble form of the ST2 receptor (sST2)
has been shown to be elevated during asthma exacerba-
tion [34]. The functional genetics of the IL1RL1 locus
are particularly advanced with key SNPs associated
with sST2 levels being identified [35]. These included
polymorphisms that altered ST2 amino acid residues
which can influence IL33 and sST2 production provid-
ing a putative mechanism [35].
Multiple other asthma susceptibility genes have now
been identified using GWAS approaches with variable
supporting evidence (Table 1). These include genes
involved in diverse roles including inflammatory cell
function and activation (IL13, IL6R, DENND1B,
LRRC32, IL2RB, IL1RL1), airway smooth muscle con-
© 2014 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons Ltd., 45 : 21–31
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traction (PDE4D), and cell apoptosis and differentiation
(GSDMB) again providing a unique insight into poten-
tially altered mechanisms in asthma. Of interest is the
large number of genes associated with epithelial cell
functions and homeostasis, e.g. IL33, IL1RL1, C11orf30
and TSLP providing further support for the accumulat-
ing data suggesting the epithelium is altered in asthma
[36]. Further supporting this concept of an altered epi-
thelial barrier in asthma is the recent finding that poly-
morphisms spanning CDHR3 are associated with severe
asthma with exacerbation [23]. CDHR3 encodes cadher-
in-related family member 3, with other family members
being involved in epithelial polarity and cell-cell inter-
actions.
Overall, the susceptibility genes identified to date
using GWAS are consistent with the hypothesis that
asthma is caused by epithelial barrier/function
abnormalities and altered innate and adaptive
Table 1. Susceptibility genes for asthma, allergic rhinitis and atopic dermatitis recently identified by Genome Wide Association Studies (GWAS)
Gene(s) Chrs Association Potential Function GWAS
IL6R 1q21 Asthma Regulatory T-cell function, T-cell differentiation 1
DENND1B 1q31 Memory T-cell functions 2†
IL1RL1 2q11 IL-33 receptor-recruitment of inflammatory cells 3–5‡, 6†, 11
PDE4D 5q12 Cell signalling, inflammation, ASM function 7
TSLP 5q22* Activates dendritic cells, Th2 immune responses 3
SLC22A4/RAD50/IL13 5q31 Organic cationic transporter/DNA repair/Th2 cytokine 6†, 8‡
HLA-DRA/DRQ 6p21* T-cell responses/many additional genes in region 3, 9, 11
CDHR3 7q22 Epithelial polarity, cell–cell contact and differentiation 6†
IL33 9p24 Recruitment/activation of inflammatory cells 3, 4, 6†
C11orf30/LRRC32 11q13 Regulates gene expression, epithelial barrier/regulatory
T-cell function
1
SMAD3 15q22 TGF-b signalling intermediate, fibrosis 3
ORMDL3/GSDMB 17q21 Sphingolipid synthesis/cell apoptosis 3, 5‡, 6†, 10§
IL2RB 22q12 Binds IL-2/IL-15, lymphoid cell differentiation 2, 3
C11orf30/LRRC32 11q13 Allergic Rhinitis Regulates gene expression, epithelial barrier/regulatory
T-cell function.
12
FLG, LCE3A 1q21* Atopic Dermatitis Epidermal differentiation and structure 13, 14, 15, 16 ¶
IL1RL1, SLC9A4 2q12* IL-33 receptor/sodium-hydrogen exchanger 15¶
IL2-IL21 4q27 T-cell survival/B cell proliferation and IgE production 15¶
SLC22A4/RAD50/IL13/KIF3A 5q31* Organic cationic transporter/DNA repair/Th2
cytokine/cilia protein
14, 15, 16 ¶
HLA-B (BAT1/TNXB/CREBL1) 6p21 T-cell responses/many additional genes in region 16
PRR5L 11p13 Cellular apoptosis 15¶
OVOL1 11q13* Development and differentiation of epidermal/epithelial
tissues
14
C11orf30/LRRC32 11q13* Regulates gene expression, epithelial barrier/regulatory
T-cell function
13, 15¶, 16
CLEC16A 16p13 Inflammatory cell function (ITAM receptor) 15¶
ZNF652 17q21 Transcriptional repressor in epithelial cancers 15¶
ADAMTS10/ACTL9 19p13* Extracellular matrix cleavage/epithelial morphology 14
TNFRSF6B 20q13* Decoy receptor, immunomodulation of T cells 14, 15¶
*Association also observed in the Asian population GWAS (see text).
Genes focused to those meeting conventional genome-wide significance (P <5 9 108) and/or independent replication in the Caucasian popula-
tion. †Childhood severe asthma with exacerbation; ‡Severe Asthma and §Childhood onset asthma. Data taken from; Asthma: 1. [67], 2. [68], 3.
[21], 4. [55], 5. [22]‡, 6. [23]†, 7. [69], 8. [70], 9. [71], 10. [20], 11. [32]. Allergic Rhinitis: 12. [37]. Atopic Dermatitis: 13. [41], 14. [42], 15. [46];
¶Using Immunochip array, 16. [48].
IL, interleukin; IL6R, IL-6 receptor; DENND1B, Denn/madd domain-containing 1b; IL1RL1, IL-1 receptor like 1; PDE4D, phosphodiesterase 4d,
cAMP-specific; ASM, airway smooth muscle; TSLP, thymic stromal lymphopoietin; Th2, T helper 2; SLC22A4, solute carrier family 22 (organic cat-
ion/zwitterion transporter), member 4; RAD50, S. cerevisiae, homolog of (DNA repair); IL13. IL-13; HLA-, Human Leukocyte Antigen, class II; CDHR3,
cadherin-related family member 3; IL33, IL-33; C11orf30, chromosome 11 open reading frame 30; LRRC32, leucine rich repeat containing 32;
SMAD3, mothers against decapentaplegic drosophila homolog 3; TGF-b transforming growth factor beta; ORMDL3, orm1-like protein 3; GSDMB,
gasdermin b; IL2RB, IL-2 receptor beta; Ig, immunoglobulin; FLG, filaggrin; LCE3A, late cornified envelope 3A; SLC9A4, solute carrier family 9, sub-
family A (NHE4, cation proton antiporter 4), member 4; IL2-IL21, interleukin 2/21; KIF3A, kinesin family member 3A; PRR5L, proline rich 5-like;
OVOL1, ovo-like 1(Drosophila); CLEC16A, C-type lectin domain family 16, member A; ZNF652, zinc finger protein 652; ADAMTS10, ADAM metallo-
peptidase with thrombospondin type 1 motif, 10; ACTL9, actin-like 9; TNFRSF6B, tumour necrosis factor receptor superfamily, member 6b, decoy.
© 2014 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons Ltd., 45 : 21–31
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immune responses. It was reported by the GABRIEL
consortium that ~49% of the lifetime risk of asthma
could be explained by the loci identified in this study
[21].
Allergic rhinitis
In contrast to asthma, there are limited data for GWA
approaches in AR in the Caucasian population with
Table 2. Susceptibility genes for allergic traits recently identified by Genome-Wide Association Studies (GWAS)
Gene(s) Chrs Association Potential Function GWAS
FCER1A 1q23 Total IgE Alpha chain of the high affinity IgE receptor 1–3
IL13/RAD50 5q31 Cytokine involved in Ig class switch/DNA repair 1–3
HLA-DRB1 6p21 T-cell responses/many additional genes in region 2
HLA-G 6p21 T-cell responses/many additional genes in region 3
HLA-A 6p21 T-cell responses/many additional genes in region 3
HLA-DQA2 6p21 T-cell responses/many additional genes in region 3
STAT6 12q13 Signal transduction linked to IgE synthesis 1–3
IL4R/IL21R 16p12 IgE regulation via IL4 and IL21 2
TMEM232/SLC25A46/TSLP 5q22 IgE to grass Tetraspan protein/transporter/activates dendritic cells 4
HLA-DRB4 6p21 T-cell responses/many additional genes in region 4
C11orf30/LRRC32 11q13 Regulates gene expression, epithelial barrier/regulatory T-cell function 4
IL1RL1 2q12 Allergic sensitisation IL-33 receptor-recruitment of inflammatory cells 5, 6
PLCL1 2q33 Intracellular signalling 6
LPP 3q27 Cell adhesion/motility/transcription 5, 6
TLR1/6/10 4p16 Pathogen recognition and activation of innate immunity 5, 6
IL2/ADAD1 4q27 Lymphocyte activity/RNA binding protein 5, 6
PTGER4 5p13 Receptor for prostaglandin E2, smooth muscle relaxation 6
SLC25A46 5q22 Member solute carrier/transporter protein family 5
WDR36/CAMK4 5q22 Cell cycle progression and gene regulation/T-cell function 6
HLA-DQA1/DQB1 6p21 T-cell responses/many additional genes in region 5, 6
HLA-B/C/MICA 6p21 T-cell responses/many additional genes in region/MHC-related protein 5, 6
MYC-PVT1 8q24 Cell cycle progression and apoptosis/regulates extracellular matrix 5
IL33 9p24 Recruitment/activation of inflammatory cells 6
GATA3 10p14 Th2 transcriptional regulator 6
C11orf30/LRRC32 11q13 Regulates gene expression, epithelial barrier/regulatory T cell function 5
STAT6 12q13 Signal transduction linked to IgE synthesis 5
FOXA1/TTC6 14q21 Embryonic development/affiliated with the lncRNA class 6
SMAD3 15q22 TGF-b signalling intermediate 6
GSDMB 17q12 Cell apoptosis 6
NFATC2 20q13 Gene expression/cellular migration 6
IL1RL1 2q12 Blood eosinophil count IL-33 receptor-recruitment of inflammatory cells. 7
IKZF2 2q34 Lymphocyte differentiation 7
GATA2 3q21 Transcription factor, inflammatory cell differentiation 7
IL5 5q23 Production and activation of eosinophils 7
SH2B3 12p24 Adaptor protein involved in T-cell function 7
Genes focused to those meeting conventional genome-wide significance (P < 5 9 108) and/or independent replication in the Caucasian popula-
tion. Total IgE: 1. [49]; .2. [21]; 3. [50], IgE to grass: 4. [37]; Allergic sensitisation by allergen-specific IgE/SPT 5. [53] or self-reported cat, house
dust-mite and pollen allergies 6. [54], Blood Eosinophil Count: 7. [55].
FCER1A, Fc fragment of IgE, high affinity I, receptor alpha polypeptide; IL, interleukin; IL13, IL-13; RAD50, S. cerevisiae, homolog of (DNA
repair); HLA-, Human Leukocyte Antigen, class II; STAT6, signal transducer and activator of transcription 6, IL4R, IL-4 receptor; IL21R, IL-21
receptor; TMEM232, transmembrane protein 232; SLC25A46, solute carrier family 25, member 46; TSLP, thymic stromal lymphopoietin;
C11orf30, chromosome 11 open reading frame 30; LRRC32, leucine rich repeat containing 32; IL1RL1, interleukin 1 receptor-like 1; PLCL1, phos-
pholipase C-like 1; LPP, LIM domain containing preferred translocation partner in lipoma; TLR1/6/10, Toll-like receptor 1/6/10; IL2, IL-2;
ADAD1, adenosine deaminase domain containing 1 PTGER4, prostaglandin E receptor 4 (subtype EP4); WDR36, WD repeat domain 36; CAMK4,
calcium/calmodulin-dependent protein kinase IV; MICA, MHC class I polypeptide-related sequence A; MYC, v-myc avian myelocytomatosis viral
oncogene homolog; PVT1, Pvt1 oncogene (non-protein coding); IL33, IL-33; GATA3, GATA binding protein 3; FOXA1, forkhead box A1; TTC6,
tetratricopeptide repeat domain 6; SMAD3, mothers against decapentaplegic drosophila homolog 3; GSDMB, gasdermin b; NFATC2, nuclear factor
of activated T-cells, cytoplasmic, calcineurin-dependent 2; IKZF2, IKAROS family zinc finger 2 (Helios); GATA2, GATA binding protein 2; IL5,
IL-5; SH2B3, SH2B adaptor protein 3.
© 2014 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons Ltd., 45 : 21–31
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only one study published to date that identified gen-
ome-wide significant association [37]. 2.2 million SNPs
were evaluated in 3933 self-reported cases of seasonal
AR versus 8965 control subjects. Only one locus
reached genome-wide significance near chromosome 11
open reading frame 30 (C11orf30) and leucine-rich
repeat containing 32 (LRRC32) at 11q13 [37]. Interest-
ingly, this locus has been previously identified in both
asthma and AD GWAS (Table 1). C11orf30 encodes
EMSY, a protein implicated in epithelial cancers [38],
potentially via mechanisms involving transcriptional
repression [39]. LRRC32 encodes a T-cell surface recep-
tor that modulates latent TGF-b and is thought to be
important for regulatory T-cell functions [40].
Atopic dermatitis
To date, there have been four GWAS for AD in the Cau-
casian population (Table 1). The first of these used a
parallel family-based and case–control design to iden-
tify associated SNPs with confidence [41]. This
approach identified two genetic loci for AD on chromo-
somes 1p21 and 11q13. Reassuringly, the chromosome
1 locus encompassed FLG previously identified as a
major AD susceptibility gene. Interestingly, the chromo-
some 11 locus encompassed C11orf30/LRRC32 previ-
ously discussed for AR and asthma, suggesting altered
epithelial biology may be a feature of AD [41].
Amongst other genes, which gave signals not meeting
stringent criteria, was HRH4 encoding histamine H4
receptor, which is important in pruritis [41]. Subsequent
GWAS for AD have used case–control designs. In the
largest study to date, Paternoster and colleagues used
meta-analyses of 5606 cases and 20 566 controls for
discovery and 5419 cases and 19 833 controls for repli-
cation to identify five loci with confidence: 1q21 (FLG),
5q31 (KIF3A), 11q13 (OVOL1), 19p13 (ADAMTS10/
ACTL9) and 20q13 (TNFRSF6B) [42]. Again, the FLG
locus was prominent in these findings and several new
loci were identified providing a potentially novel
insight into the molecular mechanisms underlying AD.
KIF3A encodes a component of the kinesin complex
involved in assembly of cilia, mice deficient in kif3a
have thinning of the epidermal layer [43], OVOL1
encodes an epidermal transcriptional repressor poten-
tially involved in keratinocyte differentiation [44] and
TNFRSF6B which encodes decoy receptor 3 (DcR3) has
multiple functions including inhibiting T-cell chemo-
taxis [45]. Ellinghaus and colleagues used an Immuno-
chip approach to investigate AD, testing 128 830 SNPs
in 2425 cases and 5449 controls, with further replica-
tion in multiple diverse ethnic populations [46]. This
study identified multiple associated loci; 1q21 (FLG),
2q12 (IL1RL1-SLC9A4), 4q27 (IL2-IL21), 11p13
(PRR5L), 11q13 (C11orf30/LRRC32), 16p13 (CLEC16A),
17q21 (ZNF652) and 20q13 (TNFRSF6B). These loci
show excellent replication for several previously identified
loci, e.g. FLG, C11orf30/LRRC32 and potentially identify
novel susceptibility genes, e.g. ZNF652, which encodes
a transcription repressor previously linked to epithelial
cancers [47]. Similarly, a recent GWAS for childhood
onset AD using 1563 cases and 4054 controls confirmed
association with loci on chromosomes 1, 5 and 11 and
provided evidence for a susceptibility locus encompassing
the HLA-B region on chromosome 6p21 (Table 1, [48]).
As for asthma, GWAS of AD in the Caucasian population
have now identified several loci with replication in three
or more studies suggesting that genetic susceptibility
involves a combination of altered barrier integrity and
altered innate and adaptive immune responses. Recent
estimates suggest that ~14.4% heritability of AD can now
be explained by currently reported loci.
Genetic risk factors associated with serum IgE, allergic
sensitisation and blood eosinophil counts
While studies using disease phenotypes such as asthma
or AD have been useful, studies in parallel have aimed
to understand genetic regulation of more quantitative
measures of allergic disease.
GWAS of serum total IgE levels
The first GWAS for IgE levels was reported by Weiding-
er and colleagues using a cohort of 1530 asthma sub-
jects and replication in four independent population-
based study samples (n = 9769 total subjects) [49]. Sig-
nificant associations between total IgE levels and loci
on chromosomes 1q23, 5q31 and 12q13 were identified
[49]. These variants map to the alpha chain of the high-
affinity receptor for IgE (FCER1A at 1q23) as well as
STAT6 (12q13), two genes involved in IgE binding and
signalling, respectively. RAD50 (5q31) homolog gene
was also identified as a potential determinant of IgE
levels [49]. A second total IgE GWAS was completed by
the GABRIEL consortium, which identified two
additional loci on chromosomes 6p21.3 and 16p12, in
asthmatic patients and non-asthmatic control subjects,
adjacent to the HLA-DRB1 and IL4R/IL21R genes,
respectively. This GWAS also confirmed the association
of loci on chromosomes 1q23 (FCER1A), 5q31 (IL13/
RAD50) and 12q13 (STAT6) with serum IgE levels [21].
Similarly, analyses in the Framingham cohort con-
firmed these three loci as containing genetic determi-
ants of total IgE and again suggested the HLA region
on 6p21 is important [50] (Table 2). Of importance was
the association of these FCER1A polymorphisms with
diseases such as asthma (P = 0.021) and AR (P = 0.015)
and with allergic sensitisation defined by skin prick test
(P = 0.03) [51].
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GWAS of allergic sensitisation
In an attempt to move from total IgE analyses to more
allergen-specific IgE approaches, Wan and colleagues
completed a GWAS for atopy, defined by elevated-spe-
cific IgE levels in 1083 cases and 2770 controls from
the British 1958 Birth Cohort [52]. A single SNP in the
13q14 (FNDC3A) locus was identified as genome-wide
significant with an additional six loci showing sugges-
tive evidence, 8q12, 8q22, 10q26, 11q24, 18q22 and
20p13. These loci were not replicated in additional
cases/controls defined by specific IgE or skin prick test
suggesting very large numbers would be required to
investigate these phenotypes and/or definition of cases
using multiple allergens may lead to heterogeneity;
analyses of single allergens may be more productive
[52]. At around the same time, the first GWAS for a
single specific IgE (grass) using 2315 cases and 10 032
control subjects was published, that identified three
loci, 5q22 (TMEM232/SLC25A46/TSLP), 6q21 (HLA-
DRB4) and 11q13 (C11orf30/LRRC32) [37]. TMEM232
encodes transmembrane protein 232, a member of the
tetraspan proteins, SLC25A46 encodes a solute carrier
protein involved in transport of metabolites, and TSLP
is involved in dendritic cell activation.
Recently, GWAS of allergic sensitisation, defined by
serum levels of specific IgE to individual allergens
house dust mite and animal dander, in 5789 atopic
individuals and 10 056 controls was reported [53]. This
study identified ten loci with replication in 6114 case
individuals and 9920 controls [53]. The loci defined by
this study have substantially increased the number of
genes associated with allergic sensitisation and include
TLR6, C11orf30, STAT6, SLC25A46, HLA-DQB1,
IL1RL1, LPP, MYC, IL2 and HLA-B [53]. The authors
suggest that these ten loci account for a minimum of
25% of IgE-defined allergic sensitisation, making these
loci significant contributors to atopic disease. The study
also confirmed several previous associations including
the relationship between STAT6 and circulating IgE
levels and the C11orf30 locus (Table 2).
A meta-analysis of genome-wide associations in
53 862 case individuals from the 23andMe, Inc. dataset
using self-reported cat, dust-mite and pollen allergies
identified a total of sixteen loci of which some were
novel; 2q33 (PLCL1), 5p13 (PTGER4), 5q22 (WDR36/
CAMK4), 9p24 (IL33), 10p14 (GATA3), 14q21 (FOXA1/
TTC6), 15q22 (SMAD3), 17q12 (GSDMB) and 20q13
(NFATC2) for sensitisation [54]. In addition, these data
showed a striking overlap with the previous large-scale
study of allergic senisitisation at six of these loci
(Table 2). However, this GWAS defined case subjects as
those with self-reported allergies and therefore is likely to
have a significant number of false-positives and to have
missed a number of loci due to these confounders [54].
GWAS of blood eosinophil count
A GWAS for blood eosinophil counts used a combined
population of 21 510 European subjects to identify five
loci, 2q12 (IL1RL1), 2q34 (IKZF2), 3q21 (GATA2), 5q23
(IL5) and 12p24 (SH2B3), showing overlap with previ-
ously identified allergic trait loci as well as disease-spe-
cific loci [55].
Overlap in GWAS results of allergic disease: ‘the atopic
march’
Tables 1 and 2 suggest that allergic diseases and traits
share a large number of genetic susceptibility loci
(Fig. 2). Of note, the IL33/IL1RL1 axis appears to be
particularly important for asthma, AD, allergic sensiti-
sation and blood eosinophil counts, suggesting this
pathway may represent an underlying mechanism and
therapeutic opportunity. Similarly, the C11orf30/
LRRC32 locus shows association to the same traits
(Tables 1 and 2). These overlapping loci may at least in
part explain the concept of the ‘atopic march’ e.g.
childhood AD leads to an increased risk of developing
asthma later in life, as there is overlapping genetic sus-
ceptibility (Fig. 2). There is clearly concordance of spe-
cific IgE loci with self-reported/doctor-diagnosed
allergic disease-based approaches for asthma, AD and
AR, e.g. C11orf30, SLC25A46, HLA-DQB1, IL1RL1,
MYC, IL2 and HLA-B. It is important to note that there
is also discordance for several loci, most evident for
trait-specific associations, e.g. the FLG locus for AD.
Due to the common occurrance of co-morbidities, it is
difficult to dissect which susceptibility loci are truly
shared and which are specific. One recent study aimed
to do this for asthma and AD by stratifying these
patients based on AD (all), AD and asthma, and AD (no
asthma) [48]. Using a cohort of 1563 childhood onset
AD cases and 4054 controls, five loci were identified as
genome-wide significant in all subjects; of interest, the
1p21 (FLG) and 5q31 (RAD50/IL13) loci achieved
markedly greater significance in the AD plus asthma
compared to the AD (no asthma) group [48]. In a simi-
lar approach, a recent study using GWAS data from
1716 asthma cases and 16 888 controls identified asso-
ciation to multiple known loci including IL1RL1; how-
ever, no significant effect of AR status was observed
[32]. Similarly, in a recent study examining both AR
and grass pollen-specific IgE in the same patients, there
was some concordance between these outcomes and
loci identified, e.g. 11q13 (C11orf30/LRRC32) and
5q22.1 (TMEM232/SLC25A46); however, other loci
appeared to be phenotype-specific, e.g. 20p11(ENTPD6)
for AR and 1p32 (EPS15) for grass sensitisation [37].
These data suggest larger prospective studies are
required to establish the different components of the
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allergic phenotype and provide a greater understanding
of heterogeneity in the underlying mechanisms.
Results of GWAS in other ethnic populations
While we have focussed to the Caucasian population in
Tables 1 and 2, it is important to note that several
GWAS for allergic conditions and traits have been com-
pleted in a range of populations, including African
American, Mexican, Korean and Japanese cohorts.
Torgerson and colleagues used diverse North American
populations including 5416 individuals with asthma of
European, American, African American or African
Caribbean, and Latino ancestry with replication in
12 649 individuals from the same ethnic groups [56].
Four previously described loci associated in Caucasian
studies were identified, 17q21, IL1RL1, IL33 and TSLP
[56]. Importantly, there appears to be some ancestry-
specific loci, e.g. the 17q21 locus was particularly rele-
vant to the Caucasian and Latino populations but not
African descent populations and the novel locus, PY-
HIN1 was restricted to individuals of African descent
only. PYHIN1 encodes pyrin and HIN domain family,
member 1 and is an interferon-inducible protein shown
to regulate IFN-b and NO production in macrophages
[57]. In the largest GWAS of asthma in the Japanese to
date, 7171 cases and 27 912 controls were used to
identify five loci, 4q31 (USP38-GAB1), 5q22 (TSLP),
6p21 (HLA), 10p14 (intergenic) and 12q13 (IKZF4) [58].
Likewise, a recent study of paediatric asthma in Japa-
nese and Korean subjects identified significant associa-
tion with the HLA-DPA1/HLA-DPB1 locus but failed to
replicate several of the loci identified in the Caucasian
population [59]. Overall, these data show some concor-
dance with asthma susceptibility loci identified in the
Caucasian population, but also identify potential ances-
try-specific loci.
Similarly, a GWAS of AD in a Chinese Han popula-
tion using a discovery sample of 1012 cases and 1362
controls followed by multiple replication cohorts identi-
fied loci at 1q21 (FLG), 5q22.1 (TMEM232/SLC25A46),
10q21 (ZNF365) and 20q13 (TNFRSF6B) [60]. The 1q,
10q and 20q loci are now convincingly replicated for
AD in the Caucasian population (Table 1). Interestingly,
the 5q22.1 (TMEM232/SLC25A46) locus only just
failed to reach genome-wide significance for AR in a
recent meta-analysis in the Caucasian population but
was associated with IgE sensitisation to grass suggest-
ing this locus is of relevance for allergic disease in the
multiple populations [37]. In a GWAS for AD in a Japa-
nese population using 3328 cases and 14 992 controls,
associations were observed for several of the loci iden-
tified in Caucasian and Chinese populations, including
FLG, C11orf30, TMEM232/SLC25A46, TNFRSF6B,
OVOL1, ACTL1 and KIF3A [61]. Importantly, several
new loci for AD were reported, including 6p21.3
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Fig. 2. Venn diagram illustrating genes identified through genome-wide association studies as associated with the allergic diseases asthma, atopic
dermatitis and allergic rhinitis. Genes highlighted in black identify those discovered in Caucasian populations, with italics defining promising
genes that nearly achieved genome-wide significance. Genes highlighted in blue identify those genes discovered in non-Caucasian populations,
while those in red identify those genes discovered in both Caucasian and populations of other ancestry.
© 2014 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons Ltd., 45 : 21–31
28 M. A. Portelli et al
(GPSM3), 11p15.4 (OR10A3-NLRP10), 3p21 (GLB1),
3q13 (CCDC80), 7p22 (CARD11), 10q21 (ZNF365) and
20q13 (CYP24A1-PFDN4) [61].
In an attempt to further define ancestry-specific
markers of serum IgE levels, a GWAS meta-analysis
has been carried out that investigated genetic variation
across African American (n = 2469), Caucasian
(n = 1564) and Latino (n = 259) racial groups in the
EVE asthma genetics consortium [62]. Here, the
authors analysed a total of 4292 subjects and identifed
ten unique regions of association with serum total IgE
levels (HLA-DQB1 PTB2, SUCLG2, MAT2B, TBX18,
SOBP, TLE4, CCDC82, WWP2 and LINC00469) [62].
Interestingly, several of these loci showed ancestry
effects, e.g. the key SNP in TBX18 may be of particu-
lar relevance in African and Latino groups but was
not informative in the Caucasian population. Very
recently, a GWAS of serum IgE levels in Japanese
subjects identified significant association with the
MHC class I locus; however, interestingly 9/32 genes
previously identified in the Caucasian population as
determinants of serum IgE showed evidence of associ-
ation indicating some cross-ethnic group associations
[63].
While further studies are required, these data suggest
there may be overlapping allergic disease susceptibility
loci spanning multiple ethnic groups, e.g. IL33/IL1RL1,
HLA locus and TSLP, as well as ancestry-specific suscep-
tibility loci, e.g. PYHIN1 in asthma.
Summary
GWAS has provided a unique insight into the genetic
basis of allergic disease, including novel information
regarding the role of potential pathways and mecha-
nisms. Associated genes include those involved in
epithelial/barrier function (e.g. FLG, CDHR3), cytokines,
their receptors and other inflammatory genes (e.g. IL13,
IL1RL1, IL33, IL2RB, TSLP), those involved in T-cell
differentiation and function (e.g. IL6R, LRRC32, HLA
genes) or those with functions relevant to specific tis-
sues affected by allergy (e.g. PDE4D, ADAMTS10).
However, these genes only account for a small propor-
tion of genetic heritability of these traits and a large
degree of genetic influence remains unaccounted for.
GWAS investigates associations to common variants
(> 5%), not rare variants or structural polymorphisms
such as insertion, deletion or copy number variation,
which may explain this missing heritability. Similarly,
gene–gene interactions and epigenetic mechanisms have
not been adequately addressed to date and may be
important considerations.
Future directions
GWAS of allergic diseases have been highly successful
in identifying genetic variation of relevance to disease
susceptibility albeit with modest effect sizes. The
future holds great promise to extend these studies par-
ticularly beyond case–control to further define endo-
types within these complex diseases as recently
reported via the use of childhood severe asthma with
exacerbation, which lead to the discovery of a novel
locus, CDHR3 [23]. In addition, a recent family exome
sequencing [64] and candidate gene resequencing [65]
suggested an increased heterogeneity in asthma and
the importance of rare variants. As costs for targeted
resequencing and whole genome sequencing continue
to decrease, this makes approaches to investigate vari-
ation per se on a large scale a real possibility. The
integration of environmental factors, known to be an
important contributing factor in allergy will be a focus
for research efforts allowing gene x environmental
interaction to be identified, with more recent studies
incorporating these parameters, e.g. interactions of AD
and smoking with asthma [32]. The environment is
particularly important for epigenetic changes driving
disease, with accumulating evidence that the epige-
nome may be important in allergic disease [66]. As
novel loci and polymorphisms are identified with con-
fidence, the long road to translate the biology of these
genetic changes begins; however, initiatives such as
the Encyclopaedia of DNA elements consortium
(ENCODE), aimed at identifying regulatory regions of
the genome and the use of expression quantitative
trait loci (eQTL) approaches will provide further insight
to functional mechanisms.
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